secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-08-18T12:00:59+00:00
Accession:  0001178913-26-004178
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio appoints Riccardo Paolo Camisasca as CMO ahead of EB613 Phase 3
--------------------------------------------------------------------------

- Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer effective Aug 18, 2026.
- He brings 30+ years experience; most recently Global Head of R&D at Sumitomo Pharma Switzerland.
- Appointment strengthens clinical team ahead of planned EB613 Phase 3 initiation for osteoporosis.
- Previously led R&D integration across Urovant, Enzyvant, Altavant, and Myovant at Sumitomo.
- CEO Miranda Toledano cites his rare combination of developing drugs across global R&D organizations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326004178/0001178913-26-004178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326004178/zk2635983.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer